PASG Key Statistics, Chart & Performance
The current stock price of PASG is 17.91 USD. In the past month the price increased by 90.77%. In the past year, price increased by 48.13%.
PASG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 60
Phone: 12678660312
PASSAGE BIO INC / PASG FAQ
What does PASG do?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Can you provide the latest stock price for PASSAGE BIO INC?
The current stock price of PASG is 17.91 USD. The price decreased by -9.77% in the last trading session.
Does PASG stock pay dividends?
PASG does not pay a dividend.
What is the ChartMill rating of PASSAGE BIO INC stock?
PASG has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PASG stock listed?
PASG stock is listed on the Nasdaq exchange.
Can you provide the number of employees for PASSAGE BIO INC?
PASSAGE BIO INC (PASG) currently has 60 employees.
Can you provide the ownership details for PASG stock?
You can find the ownership structure of PASSAGE BIO INC (PASG) on the Ownership tab.
PASG Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PASG. When comparing the yearly performance of all stocks, PASG is one of the better performing stocks in the market, outperforming 96.57% of all stocks.
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. While PASG seems to be doing ok healthwise, there are quite some concerns on its profitability.
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -14.4. The EPS increased by 38.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.04% | ||
| ROE | -145.45% | ||
| Debt/Equity | 0 |
PASG Forecast & Estimates
12 analysts have analysed PASG and the average price target is 40.39 USD. This implies a price increase of 125.53% is expected in the next year compared to the current price of 17.91.